|1.||Hutchinson, John H: 2 articles (11/2009 - 02/2008)|
|2.||Evans, Jilly F: 2 articles (11/2009 - 02/2008)|
|3.||Davidsson, Öjvind: 1 article (07/2015)|
|4.||Pettersen, Daniel: 1 article (07/2015)|
|5.||Whatling, Carl: 1 article (07/2015)|
|6.||Antoniu, Sabina Antonela: 1 article (11/2014)|
|7.||Freund, Ronald K: 1 article (06/2014)|
|8.||Serbedzija, Predrag: 1 article (06/2014)|
|9.||Frey, Lauren C: 1 article (06/2014)|
|10.||Murphy, Robert C: 1 article (06/2014)|
|1.||Eye Diseases (Eye Disease)
|2.||Asthma (Bronchial Asthma)
11/01/2009 - "The elucidation of the 3D structure of FLAP has enabled novel compound development, and several FLAP inhibitors including 2190914 (AM-103) and GSK-2190915 (both under development by GlaxoSmithKline plc) have entered phase II trials for the treatment of inflammatory disease, including asthma."
02/01/2008 - "Several FLAP inhibitors showed efficacy in early clinical trials in asthma but were not developed commercially for unpublished reasons. "
07/01/2013 - "It seems that in the near future, FLAP inhibitors can be expected to enter the market for the treatment of asthma. "
11/01/2014 - "FLAP inhibitors have emerged during the past decade as a promising therapeutic class in asthma and COPD, but there exists only a limited amount of data supporting their efficacy in these diseases. "
|3.||Cardiovascular Diseases (Cardiovascular Disease)
07/01/2015 - "With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease. "
06/15/2012 - "Pharmacological suppression of leukotriene biosynthesis by 5-lipoxygenase (5-LO)-activating protein (FLAP) inhibitors is a promising strategy to intervene with inflammatory, allergic and cardiovascular diseases. "
|4.||Chronic Obstructive Pulmonary Disease (COPD)
|5.||Neurologic Manifestations (Neurological Manifestations)
|1.||Arachidonate 5-Lipoxygenase (5 Lipoxygenase)